12/4
01:40 pm
indv
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript [Seeking Alpha]
12/3
07:02 am
indv
Indivior (NASDAQ:INDV) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Indivior (NASDAQ:INDV) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
11/21
12:41 am
indv
A Fresh Look at Indivior (INDV) Valuation Following Recent Share Price Surge [Yahoo! Finance]
Medium
Report
A Fresh Look at Indivior (INDV) Valuation Following Recent Share Price Surge [Yahoo! Finance]
11/20
04:37 pm
indv
Indivior Concludes Legacy U.S. Department of Justice Matter [Yahoo! Finance]
Medium
Report
Indivior Concludes Legacy U.S. Department of Justice Matter [Yahoo! Finance]
11/20
04:01 pm
indv
Indivior Concludes Legacy U.S. Department of Justice Matter
Medium
Report
Indivior Concludes Legacy U.S. Department of Justice Matter
11/19
09:21 am
indv
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/5
07:31 am
indv
Indivior (NASDAQ:INDV) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Indivior (NASDAQ:INDV) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
11/3
08:00 am
indv
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
Medium
Report
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
10/31
12:25 pm
indv
Indivior (NASDAQ:INDV) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $41.00 price target on the stock, up previously from $27.00.
Low
Report
Indivior (NASDAQ:INDV) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $41.00 price target on the stock, up previously from $27.00.
10/31
12:08 pm
indv
Indivior (NASDAQ:INDV) was given a new $40.00 price target on by analysts at Northland Securities.
Low
Report
Indivior (NASDAQ:INDV) was given a new $40.00 price target on by analysts at Northland Securities.
10/31
11:03 am
indv
Indivior (NASDAQ:INDV) had its "buy" rating reaffirmed by analysts at Craig Hallum.
Low
Report
Indivior (NASDAQ:INDV) had its "buy" rating reaffirmed by analysts at Craig Hallum.
10/30
12:40 pm
indv
Indivior (NASDAQ:INDV) had its price target raised by analysts at HC Wainwright from $28.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Indivior (NASDAQ:INDV) had its price target raised by analysts at HC Wainwright from $28.00 to $35.00. They now have a "buy" rating on the stock.
10/30
07:46 am
indv
Indivior Non-GAAP EPS of $0.72 beats by $0.31, revenue of $314M beats by $52.08M [Seeking Alpha]
Low
Report
Indivior Non-GAAP EPS of $0.72 beats by $0.31, revenue of $314M beats by $52.08M [Seeking Alpha]
10/30
07:00 am
indv
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
High
Report
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
10/28
10:00 am
indv
Indivior to Participate in the Stifel 2025 Healthcare Conference
Low
Report
Indivior to Participate in the Stifel 2025 Healthcare Conference
10/16
04:04 pm
indv
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th
Low
Report
Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th
10/15
11:20 pm
indv
Indivior (NasdaqGS:INDV): Fresh Clinical Data Prompts a Closer Look at Current Valuation [Yahoo! Finance]
Low
Report
Indivior (NasdaqGS:INDV): Fresh Clinical Data Prompts a Closer Look at Current Valuation [Yahoo! Finance]
10/15
08:00 am
indv
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
Medium
Report
Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
10/7
07:53 am
indv
Indivior (NASDAQ:INDV) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Medium
Report
Indivior (NASDAQ:INDV) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/1
01:54 pm
indv
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript [Seeking Alpha]
10/1
08:15 am
indv
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation [Yahoo! Finance]
Low
Report
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation [Yahoo! Finance]
10/1
08:00 am
indv
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
Low
Report
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
9/30
12:55 pm
indv
Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M [Yahoo! Finance]
Low
Report
Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M [Yahoo! Finance]
9/30
01:15 am
indv
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update [Yahoo! Finance]
9/22
01:23 am
indv
Aelis Farma Reports 2025 Half-Year Financial Results and Presents Progress and Development Outlook [Yahoo! Finance]
Low
Report
Aelis Farma Reports 2025 Half-Year Financial Results and Presents Progress and Development Outlook [Yahoo! Finance]